Mast cell leukemia (MCL) is usually a rare form of advanced SM, defined by a leukemic spread of immature MC and a short survival[14]

Mast cell leukemia (MCL) is usually a rare form of advanced SM, defined by a leukemic spread of immature MC and a short survival[14]. So far, only a few publications have reported on successful treatment of patients with MCL[4,5]. to separate this acute type of MCL from more subacute or chronic variants of MCL. Keywords:Mast cells, Mast cell leukemia, KIT, Chemotherapy, FLAG == 1. Introduction == Advanced systemic mastocytosis (SM) is usually a life-threatening condition characterized by uncontrolled growth and growth of neoplastic mast cells (MC) in various organ systems[14]. In most patients, MC are resistant against numerous targeted drugs and standard cytostatic drugs. Mast cell leukemia (MCL) is usually a rare form of advanced SM, defined by a leukemic spread of immature MC and a short survival[14]. So far, only a few publications have reported on successful treatment of patients with MCL[4,5]. Responses to polychemotherapy or targeted drugs are usually incomplete and short-lived. Therefore, hematopoietic stem cell transplantation (SCT) is usually recommended for eligible patients. However, only a few patients are transplantable because of multiorgan damage and the poor response to poly-chemotherapy. Although several different treatment strategies have been proposed, it remains unclear what type of poly-chemotherapy is usually most effective for debulking in MCL, and how many cycles are required to accomplish partial or total remission prior to SCT. We here statement on a patient with acute Balaglitazone MCL in whom polychemotherapy, consisting of fludarabine and high-dose cytosine arabinoside (ARA-C), was administered. Unexpectedly, the patient entered a good partial remission, but regrettably, remission was only short-lived and was followed by a treatment-resistant relapse. == 2. Case statement and methods == == 2.1. Case statement == A 55-12 months old female patient was referred in May 2012 because of rapidly progressing leukocytosis, anemia Balaglitazone and thrombocytopenia. The case history did not reveal mutagenic events, relevant co-morbidities or a pre-phase of mastocytosis. Physical examination disclosed moderate peripheral edema and a small hematoma on her right leg. No skin lesions and no palpable splenomegaly or lymphadenopathy was found. The peripheral blood count showed 53,300 leukocytes Rabbit Polyclonal to CBX6 Balaglitazone per microliter blood, 9.1 g/dL hemoglobin, and 74,000 platelets. A differential count revealed 17% neutrophils, 15% lymphocytes, 1% monocytes, 4% basophils, 17% metamyelocytes, 5% myelocytes, 1% promyelocytes, and 40% highly atypical immature MC. The serum tryptase level was 904 ng/mL. Moreover, an elevated alkaline phosphatase (aP, 237 U/L) and a markedly elevated lactate dehydrogenase (LDH, 2150 U/L) were found. Bone marrow (BM) investigations confirmed the diagnosis MCL. A sonographic examination revealed a slightly enlarged liver with abnormal density suggesting diffuse infiltration and moderate splenomegaly (13 cm diameter). Leukocytes were found to rapidly increase over time, with a doubling-time of less than 10 days. == 2.2. Treatment == Before and during chemotherapy, prophylactic histamine receptor blockers and prednisolone as well as prophylactic antibiotics were administered. From May 22, 2012, polychemotherapy (FLAG) was given. The patient received 30 mg/m2fludarabine i.v. on days 15 and 2 g/m2ARA-C i.v. on days 15. From day 6, she also received 30 million models G-CSF s.c. daily until granulocyte recovery. The patient was hospitalized until hematopoietic recovery and discharged between her Balaglitazone FLAG cycles. Between May and August 2012, she received 3 cycles of FLAG. == 2.3. Laboratory investigations, staging and follow-up == All Balaglitazone examinations were performed within the frame of routine diagnostics-, routine staging-, and routine follow up investigations regarded as standard in mast cell proliferative neoplasms[6]. The patient provided written knowledgeable consent before being examined and before BM or blood was obtained and analyzed. In the follow up, serial determinations of all laboratory parameters, including blood counts, differential counts, and the serum tryptase level, were performed. == 2.4. Examination of the bone marrow (BM) == BM aspirate smears were stained with WrightGiemsa and examined for the presence and percentage of MC, blast cells, and indicators.